- Joined
- 27 June 2010
- Posts
- 4,318
- Reactions
- 364
Koligo is a U.S.-based biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.
Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, in the United States. Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend its shelf life and thus expand the markets it serves.
Koligo also intends to develop a pipeline of regenerative medicine products that utilise 3D bioprinting, adipose-derived cells (regenerative cells derived from fat tissue) and other tissue processing techniques (referred to as Koligo's 3D-V technology platform) for novel cell therapy and engineered tissue products. The products that Koligo intends to develop using its 3D-V technology platform are KT-CP-203 and KT-DM-103 (Stylecel-L), engineered tissue products containing pancreatic islets for the treatment of pancreatitis, type 1 diabetes, and other pancreatic diseases.
Koligo has not yet commercialised the 3D-V technology platform, which is still subject to the completion of its development, clinical testing and regulatory approval. Further, KT-CP-203 and Stylecel-L are currently in pre-clinical stages of development.
It is anticipated that KOL will list on the ASX during March 2019.
https://koligo.net
Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, in the United States. Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend its shelf life and thus expand the markets it serves.
Koligo also intends to develop a pipeline of regenerative medicine products that utilise 3D bioprinting, adipose-derived cells (regenerative cells derived from fat tissue) and other tissue processing techniques (referred to as Koligo's 3D-V technology platform) for novel cell therapy and engineered tissue products. The products that Koligo intends to develop using its 3D-V technology platform are KT-CP-203 and KT-DM-103 (Stylecel-L), engineered tissue products containing pancreatic islets for the treatment of pancreatitis, type 1 diabetes, and other pancreatic diseases.
Koligo has not yet commercialised the 3D-V technology platform, which is still subject to the completion of its development, clinical testing and regulatory approval. Further, KT-CP-203 and Stylecel-L are currently in pre-clinical stages of development.
It is anticipated that KOL will list on the ASX during March 2019.
https://koligo.net